Kraig Biocraft Laboratories has shipped its first commercial order of spider silk yarn produced by genetically engineered silkworms that spin silk incorporating spider-silk proteins. This breakthrough overcomes the farming challenges of spiders by using silkworms, which are easier to raise and already produce silk. The spider silk yarn, noted for its strength and toughness, was sent to a major sports brand for a pilot program, marking a key milestone from research to commercial production. Kraig continues to advance its genetic engineering and production capabilities, aiming to develop fibers for diverse uses including athletic wear, protective fabrics, and medical materials.
Kraig Biocraft Laboratories' spider silk yarn innovation is the subject, with Pluang's Basic Materials sector data as context. As of Oct 06, 2026 20:18 WIB, out of 38 priced US stocks, 22 rose and 12 fell. Notable movers include ICL at USD 5.16 with a 1.98% increase and a typical hold time of 56 days, EXK at USD 8.73 with a 1.57% rise and 100% buy order activity, and LAC at USD 2.59 also up 1.57% with 100% buy order activity.
Morgan Stanley analyst Bob Huang lowered American International Group's (AIG) price target to $80 from $81, with the stock trading around $76, indicating potential upside. AIG is set to report its Q3 2026 earnings on November 3, with investors focuse...
Vertiv Holdings, a maker of power and cooling equipment for data centers, faces mixed analyst opinions with GLJ Research rating it a "Sell" and BMO Capital giving an "Outperform" rating. Despite a recent stock pullback, the company reported a 241% in...
Apogee Enterprises reported strong fiscal Q2 results with adjusted earnings of $1.17 per share, nearly double the estimated $0.59, and revenue of $391.14 million, surpassing expectations of $362.6 million. This marks a continued trend of beating esti...
McKesson received a bullish price target of $977 from Morgan Stanley, suggesting a 6.7% upside from its current price of $915.45. The company agreed to acquire Option Care Health for $32.05 per share, valuing the deal at approximately $5.8 billion in...
Ameriprise Financial has authorized an additional $5.5 billion for share repurchases through September 2028, supported by $2.1 billion in excess capital and $2.8 billion in liquidity. The company returned $1.9 billion to shareholders in H1 2026, incl...
